SecBot SecBot
SECBOTREPLAY Home › Report › TELA

TELA · TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly…

TELA Bio, Inc. · 8-K filed Apr 30, 2026 at 16:57 ET

At the news

MIXEDIMPACT 6/10

8-K filed Apr 30, 2026 at 16:57 ET

TELA Bio reported preliminary Q1 2026 revenue of ~$19.0M, slightly above the $18.5M consensus, but the filing is dominated by a near-total board overhaul: Chairman Doug Evans and three other directors are resigning, replaced by four new directors including a non-independent Chairman nominee. The board refresh, while bringing experienced MedTech executives, introduces uncertainty about strategic direction and governance stability.

  • Preliminary Q1 2026 revenue of ~$19.0M, vs $18.5M consensus and prior Q1 guidance of ~$18.5M
  • Chairman Doug Evans and three other directors (Kurt Azarbarzin, Vince Burgess, Federica O'Brien) resigning effective after 2026 Annual Meeting
  • Joseph Capper (CEO of MiMedx) nominated as Class I director and proposed as Chairman, not expected to qualify as independent
  • Three new directors appointed: Guido Neels (EW Healthcare), Guy Nohra (Alta Partners), Paul Thomas (Prominex CEO), all deemed independent

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access